The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

FDA approves BMS cell-manufacturing facility in Massachusetts

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

FDA has approved commercial production at the Bristol Myers Squibb’s cell therapy manufacturing facility in Devens, MA. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA grants accelerated approval to Augtyro for NTRK gene fusion-positive solid tumors

FDA granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account